At Leukocare, we partner with biotech and pharma teams to deliver modality-specific formulation strategies that address both scientific requirements and program realities. Whether you're working with a monoclonal antibody, a peptide, or an ATMP such as a viral vector for gene therapy or a virus-based vaccine, our team brings the insight, flexibility, and technical depth needed to guide your molecule from early development toward clinical success.
We offer expertise in both liquid and lyophilized formulations, selecting the right pathway based on your molecule’s sensitivity, intended use, and long-term stability requirements. Our development approach is designed to reduce risk, support efficient tech transfer, and ensure compatibility with primary packaging and downstream processing — all while staying aligned with your project timelines and strategic goals.
This section outlines how we approach the specific needs of each molecule type — integrating robust formulation science with real-world development experience.